Huadong Pharmaceutical Co., Ltd. (stock code: 000963) was founded in 1993 and is headquartered in Hangzhou, Zhejiang. It was listed on the Shenzhen Stock Exchange in December 1999. After more than 20 years of development, the company's business covers the entire pharmaceutical industry chain, with the pharmaceutical industry as the main focus. At the same time, it expands the pharmaceutical business, medical beauty industry and industrial microbiology business, and has developed into a large-scale comprehensive medicine integrating pharmaceutical research and development, production and distribution. Listed companies.

The company's pharmaceutical industry is deeply engaged in the research and development, production and sales of specialty, chronic disease drugs and special drugs, and has formed a complete pharmaceutical production, manufacturing and quality research system, and has formed a field mainly in chronic kidney disease, transplant immunity, endocrine, digestive system and other fields. The core product pipeline has multiple first-line clinical drugs with market advantages in China. At the same time, through independent development, external introduction, project cooperation and other methods, it focuses on innovative drugs and high technical barriers in the three core therapeutic areas of tumor, endocrine and autoimmune. Generic drugs are being researched and released. The company continues to carry out international product registration, international certification, consistency evaluation and other work, and continues to achieve results. It has formed an international pharmaceutical industry system and maintains R&D and product cooperation relationships with many international innovative R&D companies.

The company's pharmaceutical business has four major business segments: Chinese and Western medicine, medical devices, medicinal materials, ginseng and antlers, and health industry, covering pharmaceutical wholesale, pharmaceutical retail, third-party pharmaceutical flows featuring cold chain, medical e-commerce, hospital value-added services and special health Industries, further expand the fields of product agency and market expansion, the traditional Chinese medicine industry has built a full industrial chain from base planting to decoction preparation, automated decoction, and functional products, providing customers with comprehensive solutions.

The company's medical beauty business adheres to the strategy of "global operation layout, dual circulation operation development". With an international perspective, through forward-looking layout, it has more than 30 products in the field of non-invasive and minimally invasive medical beauty, of which the products have been listed at home and abroad. More than 20 models, more than 10 innovative products under research around the world, the product portfolio covers non-surgical mainstream medical beauty fields such as facial filling, facial cleaning, thread burial, skin management, body shaping, hair removal, and private repair, and has formed a comprehensive The product cluster, product quantity and coverage are among the top in the industry. Sinclair, a wholly-owned subsidiary, is the company's global medical beauty operation platform. It is headquartered in the UK and has production bases in the Netherlands, France, the United States, Switzerland and Bulgaria.

The company has been deeply engaged in the field of industrial microbiology for more than 40 years, has a deep industrial foundation and industrial transformation capabilities, and has successfully developed and manufactured a variety of microbial drugs, built a key technical system for the research and development and production of microbial products, and the scale and technology of existing microbial fermentation products. The level is at the advanced level in the industry. It has three microbial R&D platforms: China-US East China, Hunda Bio and Hunyi Bio, five industrial bases: Hangzhou Xiangfuqiao, Qiantang New District, Jiangsu Jiuyang, Meiqi Health and Meihua Hi-Tech. It currently has a large-scale scale in Zhejiang Province. The fermentation monomer workshop and the industry's advanced microbial drug production capacity, the R&D capacity covers all stages of microbial engineering technology such as strain construction, metabolic regulation, separation and purification, enzyme catalysis, and synthesis modification. It has formed microbial project research and development, pilot and commercialization. A complete manufacturing system guaranteed by production, engineering and public system.